Advance in nasal mucoadhesive microspheres For treating alzheimer’s disease: A comprehensive review

Arbind Mahato, S. Rajarajan, Beny Baby and K Ramesh

Progressions in nasal mucoadhesive microspheres speak to a promising technique for the treatment of Alzheimer's disease, a neurological disorder affecting roughly 3% of the elderly population worldwide. Current therapeutic alternatives, primarily cholinesterase inhibitors and NMDA receptor antagonists, mainly provide symptomatic relief and fail in addressing the underlying neurobiological components of the disease, such as amyloid-β aggregation and oxidative stress. Nasal drug delivery systems offer a significant advantage by bypassing the blood-brain barrier, enhancing drug delivery, and enabling targeted delivery to the central nervous system. Mucoadhesive microspheres enhance drug retention within the nasal cavity, allow controlled drug release, and improve treatment compliance, particularly among elderly and pediatric populations. This comprehensive audit highlights the potential of these inventive medicate conveyance frameworks to revolutionize advertising administration by giving non-invasive, compelling, and targeted therapeutic alternatives.

Keywords – Alzheimer's disease, Nasal drug delivery, Mucoadhesive microspheres, Blood-brain barrier, Neurological disorders.